Emerging or re-emerging infections that can be used for bioterrorism;Infections émergentes ou ré-émergentes utilisables pour le bioterrorisme

Presse Medicale

Volumn 34, Issue 2 II, 2005, Pages 149-155

  Bossi, Philippe ^a   Guihot, Amélie ^a   Bricaire, François ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACILLUS ANTHRACIS; BIOLOGICAL WARFARE; BRUCELLA; BRUCELLOSIS; BURKHOLDERIA MALLEI; CHOLERA; CLOSTRIDIUM BOTULINUM; COXIELLA BURNETII; DEATH; DIPHTHERIA; ENCEPHALITIS VIRUS; FRANCISELLA TULARENSIS; HEALTH PRACTITIONER; HUMAN; INFECTION; LEGIONNAIRE DISEASE; MELIOIDOSIS; NONHUMAN; PRACTICE GUIDELINE; Q FEVER; REVIEW; RICKETTSIOSIS; SALMONELLOSIS; SHIGELLOSIS; TUBERCULOSIS; TULAREMIA; TYPHOID FEVER; VIBRIO CHOLERAE; VIRUS HEMORRHAGIC FEVER; YERSINIA PESTIS;

EID: 13244256868     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0755-4982(05)83895-3     Document Type: Review

References (41)

1. McGovern T, Friedlander A. Plague. In: Textbook of Military Medicine, Medical Aspects of Chemical and Biological Warfare, Office of the Surgeon General 1997; 23: 479-502.
2. Slack P. The black death: past and present. Trans R Soc Trop Med Hyg 1989; 83: 461-3.
3. Henderson D, Inglesby T, Bartlett J et al. Smallpox as a biological weapon. Consensus statement. JAMA 1999; 281: 2127-37.
4. Meselson M, Guillemin J, Hugh-Jones M et al. The Sverdlovsk anthrax outbreak of 1979. Science 1994; 266: 1202-8.
5. Jernigan J, Stephens D, Ashford D et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis 2001; 7: 933-44.
6. Centers for Disease Control and Prevention. Update: investigation of bioterrorism-related anthrax-Connecticut, 2001. MMWR 2001; 50: 1077-9.
7. Tegnell A, Bossi P, Baka A et al. The European commission's task force on bioterrorism. Emerg Infect Dis 2003: http://www.cdc.gov/ncidod/EID/ vol9no10/03-03-0368.htm
8. Infections et bioterrorisme:www.afssaps.sante.fr
9. The European Agency for the Evaluation of Medicinal Products/CPMP guidance document on use of medicinal products for treatment and prophylaxis of biological agents that might be used as weapons of bioterrorism. Feb 2002; www.emea.eu.int
10. Anthrax; Interim PHLS guidelines for action in the event of a deliberate release: www.phls.org.uk/facts/deliberate_releases.htm
11. Inglesby T, O'Toole T, Henderson D et al. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 2002; 287: 2236-52.
12. Health Aspects of Chemical and Biological Weapons. Geneva, Switzerland: World Health Organization; 1970.
13. Centers for Disease Control and Prevention. Use of anthrax vaccine in the United States; recommendations of the advisory committee on immunization practices (ACIP). MMWR 2000; 4: RR-15.
14. Bossi P, Bricaire F. Maladie du charbon à l'heure du bioterrorisme. Presse Med 2003; 32: 167-73.
15. Friedlander A, Pittman P, Parker G. Anthrax vaccine: evidence for safety and efficacy against inhalational anthrax. JAMA 1999; 282: 2104-6.
16. Inglesby TV, Dennis DT, Henderson DA et al. Plague as a biological weapon. Medical and Public Health Management. JAMA 2000; 283: 2281-90.
17. Bossi P, Bricaire F. La peste, acte possible de bioterrorisme. Presse Med 2003; 32: 804-7.
18. Levison M. Lessons learned from history on mode of transmission for control of pneumonic plague. Curr Infect Dis Rep 2000; 2: 269-71.
19. Franz D, Jahrling P, Friedlander A et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997; 278: 399-411.
20. Inglesby T, Grossman R, O'Toole T. A plague on your city: observations from TOPOFF. Clin Infect Dis 2001; 32: 436-45.
21. Tiball R, Williamson E. Vaccination against bubonic and pneumonic plague. Vaccine 2001; 19: 4175-84.
22. Dennis DT, Inglesby TV, Henderson DA et al. Tularemia as a Biological Weapon. Medical and Public Health Management. JAMA 2001; 285: 2763-73.
23. Bossi P, Bricaire F. La tularémie: arme potentielle du bioterrorisme. Presse Med 2003; 32: 1123-7.
24. Franz D, Jahrling P, Friedlander A et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997; 278: 399-411.
25. Bossi P, Bricaire F. Variole: agent du bioterrorisme. Presse Med 2002; 38: 1813-7.
26. Bray M, Martinez M, Kefauver D, West M, Roy C. Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir. Antiviral Res 2002; 54: 129-42.
27. Frey S, Couch R, Tacket C et al. Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med 2002; 346: 1265-74.
28. Hendriks J, Tegnell A, Bossi P for Task Force on Bioterrorism (BICHAT), Public Health Directorate, European Commission, Luxembourg. United States smallpox response plans : a commentary from the Bioterrorism Taskforce (BICHAT) perspective. Eurosurveillance Weekly 2002; 6: 021024 (http://www. eurosurveillance.org/ew/2002/ 021024.asp)
29. Arnon S, Schechter R, Inglesby T et al. Botulinum Toxin as a Biological weapon. JAMA 2001; 285: 1059-70.
30. Bossi P, Bricaire F. La toxine botulique, arme bioterroriste. Presse Med 2003; 32: 463-5.
31. Franz D, Jahrling P, Friedlander A et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997; 278: 399-411.
32. Middlebrook J, Franz D. Botulinum toxins. In: Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare, Zajtchuk R ed. US Department of the Army, Surgeon General, and the Borden Institure, Washington, DC 1997: 643-54.
33. Byrne M, Smith L. Development of vaccines for prevention of botulism. Biochimie 2000; 82: 955-66.
34. Hoover D, Friedlander A. Brucellosis. In: Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare, Zajtchuk R ed. US Department of the Army, Surgeon General, and the Borden Institure, Washington, DC 1997: 513-21.
35. Norlander L. Q fever epidemiology and pathogenesis. Microbes Infect 2000; 2: 417-24.
36. Franz D, Jahrling P, Friedlander A et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997; 278: 399-411.
37. Sawyer L, Fishbein D, McDale D. Q fever; current concepts. Rev Infect Dis 1987; 9: 935-46.
38. Srinivasan A, Kraus CN, DeShazer D, Becker PM, Dick JD, Spacek L et al. Glanders in a military research microbiologist. N Engl J Med 2001; 345: 256-8.
39. Borio L, Inglesby T, Schmaljohn A et al. Hemorrhagic fever viruses as a biological weapon: medical and public health management. JAMA 2002; 287: 2391-405.
40. Smith J, Davis K, Hart M et al. Viral encephalitides. In: Textbook of Military Medicine, Medical Aspects of Chemical and Biological Warfare, Office of the Surgeon General. 1997; 28: 561-89.
41. Fine A, Layton M. Lessons from the West Nile viral encephalitis outbreak in New York City, 1999: implications for bioterrorism preparedness. Clin Infect Dis 2001; 32: 277-82.